Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04332302
Other study ID # SE1911600154
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date January 15, 2020
Est. completion date December 21, 2021

Study information

Verified date October 2020
Source Technical University of Madrid
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Diabetes is a disease with a high impact in the population older than 65 years old. Some indications suggest that diabetes in the old age aggravate the negative effects of ageing, as the loss of muscle mass and strength, bringing the patients to a situation of vulnerability and elevated risk of disability and death known as "frailty syndrome". Recently, scientists have observed that if older population train with musculation machines emphasising the muscular power, it is possible to have an impact on a disminution of frailty and restoring the physical functionality. This project deeps in the physiological and molecular mechanisms that underlie to improvements in the frail diabetic patients.


Description:

It is hypothesised that: 1. High intensity training (strength-power) prescribed properly in an individualised form and supervised could influence significantly on the phenotypic response in the DM type 2: decreasing the level of clinical severity, disability and frailty, improving quality of life and glycaemic control, functional capacity and body composition (especially the muscle mass) of the diabetic patients (type 2) older than 65 years old. 2. Part of the training adaptations in diabetic patients (type 2) older than 65 years old could due to physiological conditions as the systemic level of biomarkers as PDEF in these patients. 3. Part of the training adaptations in diabetic patients (type 2) could be influenced by the characterisation of associated genes to the different types of DM type 2 recently characterised. The principal aims are: 1. To evaluate the effectiveness of a novel intervention based on strength-power exercise in individuals older than 65 years old with DM type 2 and frailty in term of: level of clinical severity, disability, glycaemic control, quality of life, functional capacity, state of frailty and body composition. 2. To establish whether PDEF serves as diagnostic and prediction biomarker to training response, providing an objective and accessible method that would stratify the response to the intervention helping with the patients screening. 3. To determine the role of characterised genetic variants in the different subgroups of DM type 2 in the level of response to the training stimuli. Study design Longitudinal intervention stratified study, controlled and single-blinded, with a group of intervention and control group. Based on data from a previous study recently published by the collaborators of this project. The sample size was calculated to get statistically significant differences in the physical functionality using ANCOVA and performing a bilateral contrast with alpha=0.05 of the effect of the group (with any of the independent variables), and it is needed 30 subjects by group (total n=60) to get a statistical power of 80%, with a partial eta ≥ 0.101 (value that corresponds with the size of the moderate effect). Exercise program The intervention period will have a duration of 12 weeks, in which the training group will perform 2 sessions per week (24 sessions in total), while the control group will not perform any type of intervention, following their normal lifes and the habitual medical cares. The experimental group will perform a program focused on the muscle power training, in which there will be included exercise of upper limbs (chest press) and lower limbs (leg press). The exercises will be performed in muscle-building machines available in the reference institutions of the collaborators. It is important to point out that the intensity in the exercises will be individualised for any patient through a test of determination of muscle power validated previously by the consortium of researchers and the subjects will perform the exercises at this intensity at which the subjects will develop their maximal muscle performance, with the performance of 3-4 bouts of 8 repetitions in each exercise. After the third week of intervention, it will be put the attention to the speed of execution. The duration of each session has been estimated in 20-30 minutes. Finally, the subjects in the control group will serve to compare the interventions with exercise and the clinical conventional treatment, as well as to determine whether the training program is able to restore the functional capacity in a similar way in diabetic patients without frailty.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 41
Est. completion date December 21, 2021
Est. primary completion date May 15, 2020
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - Sign an informed consent. - Older than 65 years old with Type 2 Diabetes Mellitus diagnosed in a minimum of 2 previous years. - Being diagnosed frail, pre-frail or no frail. Exclusion Criteria: - Barthel's index lower than 60 points. - Incapacity to complete the SPPB fitness test. - Score lower than 20 points in the Mini Mental State Examination. - Cardiovascular event in the previous 6 months following the New York Heart Association (NYHA) classification. - Patients clinically unstable by the investigator's judgement. - Terminal disease (life expectancy lower than 6 months). - Participation in another study that could interfere in the results of the current research.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Power resistance training
Participants will take part in an intervention of 12 weeks duration in which they will train with musculation machines.

Locations

Country Name City State
Spain Instituto Nacional de Educación Física Madrid

Sponsors (4)

Lead Sponsor Collaborator
Technical University of Madrid Castilla-La Mancha Health Service, Spanish Society of Diabetes, University of Castilla-La Mancha

Country where clinical trial is conducted

Spain, 

References & Publications (8)

Alcazar J, Guadalupe-Grau A, García-García FJ, Ara I, Alegre LM. Skeletal Muscle Power Measurement in Older People: A Systematic Review of Testing Protocols and Adverse Events. J Gerontol A Biol Sci Med Sci. 2018 Jun 14;73(7):914-924. doi: 10.1093/gerona/glx216. — View Citation

Alcazar J, Rodriguez-Lopez C, Ara I, Alfaro-Acha A, Mañas-Bote A, Guadalupe-Grau A, García-García FJ, Alegre LM. The Force-Velocity Relationship in Older People: Reliability and Validity of a Systematic Procedure. Int J Sports Med. 2017 Dec;38(14):1097-1104. doi: 10.1055/s-0043-119880. Epub 2017 Nov 10. — View Citation

Alcazar J, Rodriguez-Lopez C, Ara I, Alfaro-Acha A, Rodríguez-Gómez I, Navarro-Cruz R, Losa-Reyna J, García-García FJ, Alegre LM. Force-velocity profiling in older adults: An adequate tool for the management of functional trajectories with aging. Exp Gerontol. 2018 Jul 15;108:1-6. doi: 10.1016/j.exger.2018.03.015. Epub 2018 Mar 20. — View Citation

García-García FJ, Carcaillon L, Fernandez-Tresguerres J, Alfaro A, Larrion JL, Castillo C, Rodriguez-Mañas L. A new operational definition of frailty: the Frailty Trait Scale. J Am Med Dir Assoc. 2014 May;15(5):371.e7-371.e13. doi: 10.1016/j.jamda.2014.01.004. Epub 2014 Mar 2. — View Citation

Garcia-Garcia FJ, Gutierrez Avila G, Alfaro-Acha A, Amor Andres MS, De Los Angeles De La Torre Lanza M, Escribano Aparicio MV, Humanes Aparicio S, Larrion Zugasti JL, Gomez-Serranillo Reus M, Rodriguez-Artalejo F, Rodriguez-Manas L; Toledo Study Group. The prevalence of frailty syndrome in an older population from Spain. The Toledo Study for Healthy Aging. J Nutr Health Aging. 2011 Dec;15(10):852-6. — View Citation

Guadalupe-Grau A, Aznar-Laín S, Mañas A, Castellanos J, Alcázar J, Ara I, Mata E, Daimiel R, García-García FJ. Short- and Long-Term Effects of Concurrent Strength and HIIT Training in Octogenarians with COPD. J Aging Phys Act. 2017 Jan;25(1):105-115. doi: 10.1123/japa.2015-0307. Epub 2016 Aug 24. — View Citation

Guadalupe-Grau A, Carnicero JA, Gómez-Cabello A, Gutiérrez Avila G, Humanes S, Alegre LM, Castro M, Rodríguez-Mañas L, García-García FJ. Association of regional muscle strength with mortality and hospitalisation in older people. Age Ageing. 2015 Sep;44(5):790-5. doi: 10.1093/ageing/afv080. Epub 2015 Jul 11. — View Citation

Losa-Reyna J, Baltasar-Fernandez I, Alcazar J, Navarro-Cruz R, Garcia-Garcia FJ, Alegre LM, Alfaro-Acha A. Effect of a short multicomponent exercise intervention focused on muscle power in frail and pre frail elderly: A pilot trial. Exp Gerontol. 2019 Jan;115:114-121. doi: 10.1016/j.exger.2018.11.022. Epub 2018 Dec 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Glycosylated Hemoglobin (Hemoglobin A1c) at 12 weeks Percentage 0 and 12 weeks.
Primary Change from Baseline Homeostasis Model Assessment - Beta cells (HOMA2-B) at 12 weeks Percentage 0 and 12 weeks.
Primary Change from Baseline Homeostasis Model Assessment - Insuline Resistance (HOMA2-IR) at 12 weeks Percentage 0 and 12 weeks.
Primary Change from Baseline Fried frailty score at 6 and 12 weeks Level of frailty assessed by Fried Criteria. Intermediate or prefrail: 1 or 2 criteria present. Positive for frailty phenotype: =3 criteria present. 0, 6 and 12 weeks.
Primary Change from Baseline Functional capacity at 6 and 12 weeks Level of functional capacity assessed by the test SPPB. Scores 0-3: Very low physical function; Scores 4-6: Low physical function; Scores 7-9: Moderate physical function; Scores 10-12: High physical function 0, 6 and 12 weeks.
Primary Change from Baseline Disability at 6 and 12 weeks Level of disability assessed by the Barthel test. A participant scoring 0 points would be dependent in all assessed activities of daily living, whereas a score of 100 would reflect independence in these activities. 0, 6 and 12 weeks.
Primary Functional mobility at 6 and 12 weeks Level of functional mobility assessed by the Lawton test. A scale from 0 to 8, expressing higher scores better levels of independence. 0, 6 and 12 weeks.
Primary Change from Baseline Muscular power at 6 and 12 weeks Watts. 0, 6 and 12 weeks.
Primary Change from Baseline Levels of strength at 6 and 12 weeks Load (kg). 0, 6 and 12 weeks.
Primary Change from Baseline Bone Mineral Density at 12 weeks g/cm3 0 and 12 weeks.
Primary Change from Baseline Pigment Epitelium Derived Factor (PEDF) at 12 weeks Circulating level of PDEF assessed by Western Blot. 0 and 12 weeks.
Primary Genotyping of TCF7L2 (rs7903146) Assessed by Real-time PCR. 0 week.
Primary Genotyping of TM6SF2 (rs10401969) Assessed by Real-time PCR. 0 week.
Primary Genotyping of HLA (rs2854275) Assessed by Real-time PCR. 0 week.
Secondary Change from Baseline Body Mass Index at 6 and 12 weeks Kg by square meters. 0, 6 and 12 weeks.
Secondary Change from Baseline Waist circumference at 6 and 12 weeks Meters. 0, 6 and 12 weeks.
Secondary Change from Baseline Blood pressure (systolic and diastolic) at 6 and 12 weeks mmHg. 0, 6 and 12 weeks.
Secondary Change from Baseline Concentration of Triglycerides at 12 weeks mg/dL. 0 and 12 weeks.
Secondary Change from Baseline Concentration of Total Cholesterol at 12 weeks mg/dL. 0 and 12 weeks.
Secondary Change from Baseline Concentration of HDL Cholesterol at 12 weeks mg/dL. 0 and 12 weeks.
Secondary Change from Baseline Concentration of LDL Cholesterol at 12 weeks mg/dL. 0 and 12 weeks.
Secondary Change from Baseline Subjective level of quality of life at 12 weeks Level of quality of life assessed by the test EuroQoL index, EQ-5D-5L. The score is the time trade-off (TTO). Scale from 11111 to 55555 being the higher the best health related quality of life. 0 and 12 weeks.
Secondary Change from Baseline Physical activity at 12 weeks Accelerometry, counts/min. 0 and 12 weeks.
Secondary Change from Baseline Balance at 12 weeks Level of balance assessed in a force platform. Newtons. 0 and 12 weeks.
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2